{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:23:57Z","timestamp":1792567437842,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T00:00:00Z","timestamp":1351209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s12020-012-9819-4","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T08:20:14Z","timestamp":1351153214000},"page":"237-246","source":"Crossref","is-referenced-by-count":78,"title":["Combination therapy with risedronate and teriparatide in male osteoporosis"],"prefix":"10.1007","volume":"44","author":[{"given":"Marcella D.","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E.","family":"Cusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James","family":"Sliney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald J.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,10,26]]},"reference":[{"issue":"2","key":"9819_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/qjmed\/91.2.71","volume":"91","author":"R Eastell","year":"1998","unstructured":"R. Eastell, I.T. Boyle, J. Compston, C. Cooper, I. Fogelman, R.M. Francis, D.J. Hosking, D.W. Purdie, S. Ralston, J. Reeve, D.M. Reid, R.G. Russell, J.C. Stevenson, Management of male osteoporosis: report of the UK Consensus Group. QJM 91(2), 71\u201392 (1998)","journal-title":"QJM"},{"issue":"12","key":"9819_CR2","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"O. Johnell, J.A. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17(12), 1726\u20131733 (2006). doi:\n                    10.1007\/s00198-006-0172-4","journal-title":"Osteoporos. Int."},{"issue":"9156","key":"9819_CR3","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"J.R. Center, T.V. Nguyen, D. Schneider, P.N. Sambrook, J.A. Eisman, Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156), 878\u2013882 (1999). doi:\n                    10.1016\/S0140-6736(98)09075-8","journal-title":"Lancet"},{"issue":"11","key":"9819_CR4","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00198-011-1632-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22(11), 2789\u20132798 (2011). doi:\n                    10.1007\/s00198-011-1632-z","journal-title":"Osteoporos. Int."},{"issue":"9","key":"9819_CR5","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1210\/jc.85.9.3069","volume":"85","author":"ES Kurland","year":"2000","unstructured":"E.S. Kurland, F. Cosman, D.J. McMahon, C.J. Rosen, R. Lindsay, J.P. Bilezikian, Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85(9), 3069\u20133076 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"9819_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, J.M. Kaufman, A.D. Clancy, G.A. Gaich, The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18(1), 9\u201317 (2003). doi:\n                    10.1359\/jbmr.2003.18.1.9","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"9819_CR7","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"343","author":"E Orwoll","year":"2000","unstructured":"E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343(9), 604\u2013610 (2000). doi:\n                    10.1056\/NEJM200008313430902","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"9819_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1359\/jbmr.081214","volume":"24","author":"S Boonen","year":"2009","unstructured":"S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24(4), 719\u2013725 (2009). doi:\n                    10.1359\/jbmr.081214","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"9819_CR9","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/jbmr.119","volume":"25","author":"ES Orwoll","year":"2010","unstructured":"E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Mesenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5\u00a0mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25(10), 2239\u20132250 (2010). doi:\n                    10.1002\/jbmr.119","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"9819_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12020-011-9570-2","volume":"41","author":"G Mazziotti","year":"2012","unstructured":"G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58\u201369 (2012). doi:\n                    10.1007\/s12020-011-9570-2","journal-title":"Endocrine"},{"issue":"13","key":"9819_CR11","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, R.M. Neer, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349(13), 1216\u20131226 (2003). doi:\n                    10.1056\/NEJMoa035725NEJMoa035725","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"9819_CR12","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1210\/jc.2006-0190","volume":"91","author":"JS Finkelstein","year":"2006","unstructured":"J.S. Finkelstein, B.Z. Leder, S.M. Burnett, J.J. Wyland, H. Lee, A.V. de la Paz, K. Gibson, R.M. Neer, Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J. Clin. Endocrinol. Metab. 91(8), 2882\u20132887 (2006). doi:\n                    10.1210\/jc.2006-0190","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"9819_CR13","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","volume":"95","author":"JS Finkelstein","year":"2010","unstructured":"J.S. Finkelstein, J.J. Wyland, H. Lee, R.M. Neer, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95(4), 1838\u20131845 (2010). doi:\n                    10.1210\/jc.2009-1703","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"13","key":"9819_CR14","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13), 1207\u20131215 (2003). doi:\n                    10.1056\/NEJMoa031975NEJMoa031975","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"9819_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12020-011-9554-2","volume":"41","author":"J Compston","year":"2012","unstructured":"J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1), 11\u201318 (2012). doi:\n                    10.1007\/s12020-011-9554-2","journal-title":"Endocrine"},{"issue":"11","key":"9819_CR16","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1359\/JBMR.050714","volume":"20","author":"C Deal","year":"2005","unstructured":"C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20(11), 1905\u20131911 (2005). doi:\n                    10.1359\/JBMR.050714","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"9819_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, W. Wu, A. Mangood, R.G. Russell, F.H. Ebetino, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5), 617\u2013627 (2006). doi:\n                    10.1016\/j.bone.2005.05.003","journal-title":"Bone"},{"issue":"1","key":"9819_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/JBMR.040920","volume":"20","author":"CJ Rosen","year":"2005","unstructured":"C.J. Rosen, M.C. Hochberg, S.L. Bonnick, M. McClung, P. Miller, S. Broy, R. Kagan, E. Chen, R.A. Petruschke, D.E. Thompson, A.E. de Papp, Treatment with once-weekly alendronate 70\u00a0mg compared with once-weekly risedronate 35\u00a0mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20(1), 141\u2013151 (2005). doi:\n                    10.1359\/JBMR.040920","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"9819_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1385\/JCD:4:2:105","volume":"4","author":"SL Bonnick","year":"2001","unstructured":"S.L. Bonnick, C.C. Johnston Jr, M. Kleerekoper, R. Lindsay, P. Miller, L. Sherwood, E. Siris, Importance of precision in bone density measurements. J Clin Densitom 4(2), 105\u2013110 (2001)","journal-title":"J Clin Densitom"},{"issue":"9","key":"9819_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137\u20131148 (1993). doi:\n                    10.1002\/jbmr.5650080915","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"9819_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guanabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26(3), 503\u2013511 (2011). doi:\n                    10.1002\/jbmr.238","journal-title":"J. Bone Miner. Res."},{"issue":"19","key":"9819_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19), 1434\u20131441 (2001)","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"9819_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1359\/jbmr.090711","volume":"25","author":"B Borah","year":"2010","unstructured":"B. Borah, T. Dufresne, J. Nurre, R. Phipps, P. Chmielewski, L. Wagner, M. Lundy, M. Bouxsein, R. Zebaze, E. Seeman, Risedronate reduces intracortical porosity in women with osteoporosis. J. Bone Miner. Res. 25(1), 41\u201347 (2010). doi:\n                    10.1359\/jbmr.090711","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"9819_CR24","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93(10), 3785\u20133793 (2008). doi:\n                    10.1210\/jc.2008-0353","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"9819_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","volume":"50","author":"D Gatti","year":"2012","unstructured":"D. Gatti, O. Viapiana, S. Adami, L. Idolazzi, E. Fracassi, M. Rossini, Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3), 739\u2013742 (2012). doi:\n                    10.1016\/j.bone.2011.11.028","journal-title":"Bone"},{"issue":"3","key":"9819_CR26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","volume":"23","author":"SA Polyzos","year":"2012","unstructured":"S.A. Polyzos, A.D. Anastasilakis, C. Bratengeier, W. Woloszczuk, A. Papatheodorou, E. Terpos, Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2014the six-month effect of risedronate and teriparatide. Osteoporos. Int. 23(3), 1171\u20131176 (2012). doi:\n                    10.1007\/s00198-010-1525-6","journal-title":"Osteoporos. Int."},{"issue":"1","key":"9819_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12020-012-9691-2","volume":"42","author":"JF Griffith","year":"2012","unstructured":"J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42(1), 39\u201351 (2012). doi:\n                    10.1007\/s12020-012-9691-2","journal-title":"Endocrine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-012-9819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-012-9819-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-012-9819-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-012-9819-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T23:29:48Z","timestamp":1581982188000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-012-9819-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["9819"],"URL":"https:\/\/doi.org\/10.1007\/s12020-012-9819-4","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,26]]}}}